Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
January 20, 2020
Fred Hutch science and research highlights 2019
Articles showcasing some of the most significant advances in immunotherapy, cell biology and more
New study aims to transform myeloma therapy into cure
$4M grant funds Dr. Geoffrey Hill’s bench-to-bedside research to enhance immune-boosting power of autologous blood stem cell transplantation
Mystery solved: How graft-vs.-host disease starts in the gut
Microbiome triggers top killer after bone marrow transplant — and there’s a potential way to stop it
Washington’s CARE Fund awards Dr. Lucas Sullivan Distinguished Researcher grant
Sullivan studies metabolic pathways required for cancer growth, progression
T cells from autologous transplants can combat multiple myeloma
From the Hill Laboratory, Clinical Research Division
Scientists learn how common virus reactivates after transplantation
New Science paper describes how antibody-producing B cells, not disease-fighting T cells, protect against reactivation of cytomegalovirus
Rethinking an old viral foe
Why does a common virus plague bone marrow transplant patients? New study challenges dogma, opens door to new therapies.
Standard myeloma treatment reveals itself as an immunotherapy
Mouse study shows how transplanting patients’ own healthy blood stem cells can curb cancer, opening door to better treatments
Washington’s Andy Hill Cancer Research Endowment awards $1.5M to 3 Fred Hutch researchers
Scientists will use funds to expand research in graft-vs.-host disease, chemoprevention and cancer immunology
Dr. Geoffrey Hill 3rd recipient of José Carreras/E. Donnall Thomas Endowed Chair for Cancer Research
Endowments provide faculty with freedom and flexibility to pursue critical research endeavors
What’s new in combatting chronic graft-vs.-host disease
Decades after the development of bone marrow transplant, researchers are making headway against one of its most common and deadly side effects